158 related articles for article (PubMed ID: 7838917)
1. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; Paradis M; Bourin M
Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917
[TBL] [Abstract][Full Text] [Related]
2. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
3. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
Maron E; Tõru I; Vasar V; Shlik J
J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
[TBL] [Abstract][Full Text] [Related]
4. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
5. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
6. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
7. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
8. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
9. The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4.
Le Mellédo JM; Arthur H; Dalton J; Woo C; Lipton N; Bellavance F; Koszycki D; Boulenger JP; Bradwejn J
J Psychosom Res; 2001 Sep; 51(3):513-20. PubMed ID: 11602221
[TBL] [Abstract][Full Text] [Related]
10. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers.
Tõru I; Aluoja A; Võhma U; Raag M; Vasar V; Maron E; Shlik J
Psychiatry Res; 2010 Jul; 178(2):342-7. PubMed ID: 20471107
[TBL] [Abstract][Full Text] [Related]
11. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder.
Ströhle A; Kellner M; Holsboer F; Wiedemann K
Biol Psychiatry; 1999 Feb; 45(3):321-6. PubMed ID: 10023509
[TBL] [Abstract][Full Text] [Related]
12. Response to flumazenil in women with premenstrual dysphoric disorder.
Le Mellédo JM; Van Driel M; Coupland NJ; Lott P; Jhangri GS
Am J Psychiatry; 2000 May; 157(5):821-3. PubMed ID: 10784479
[TBL] [Abstract][Full Text] [Related]
13. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder.
Woods SW; Charney DS; Silver JM; Krystal JH; Heninger GR
Psychiatry Res; 1991 Feb; 36(2):115-27. PubMed ID: 1850142
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity to cholecystokinin-tetrapeptide in major depression.
Koszycki D; Copen J; Bradwejn J
J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
[TBL] [Abstract][Full Text] [Related]
15. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
[TBL] [Abstract][Full Text] [Related]
16. Effects of the benzodiazepine antagonist flumazenil in PTSD.
Randall PK; Bremner JD; Krystal JH; Nagy LM; Heninger GR; Nicolaou AL; Charney DS
Biol Psychiatry; 1995 Sep; 38(5):319-24. PubMed ID: 7495926
[TBL] [Abstract][Full Text] [Related]
17. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
18. Flumazenil challenge in social phobia.
Coupland NJ; Bell C; Potokar JP; Dorkins E; Nutt DJ
Depress Anxiety; 2000; 11(1):27-30. PubMed ID: 10723632
[TBL] [Abstract][Full Text] [Related]
19. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
Zwanzger P; Baghai TC; Schuele C; Ströhle A; Padberg F; Kathmann N; Schwarz M; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
[TBL] [Abstract][Full Text] [Related]
20. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
Kellner M; Yassouridis A; Jahn H; Wiedemann K
Psychopharmacology (Berl); 1997 Sep; 133(1):55-61. PubMed ID: 9335081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
